ENDONOVO THERAPEUTICS, INC. financials

ENDV CIK 0001528172

Source: EDGAR filings · Built 2026-06-19T02:18:24Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Free Cash Flow -2.54M -2.89M
EBITDA -2.62M -1.58M -2.26M -3.16M -3.51M -4.59M
Working Capital -33.37M -17.61M -16.78M -23.56M -15.10M -13.30M
Net Debt 7.16M 7.17M 6.82M 6.86M 13.83M 11.73M
Gross Margin 92.62% 79.50% 60.57% 69.89% 84.47%
Operating Margin -2411.69% -3045.68% -1756.49% -1228.08% -4995.33%
Net Margin -13649.17% -4247.17% -238.60% -5582.37% -7729.53%
Return on Equity (ROE) 57.41% 19.68% 2.75% 84.45% 56.50% 113.19%
Return on Assets (ROA) -1441.92% -154.69% -15.17% -528.74% -151.71% -234.38%
Current Ratio 0.00× 0.01× 0.00× 0.00× 0.02× 0.01×
Debt-to-Equity -0.22× -0.46× -0.48× -0.34× -1.25× -1.24×
Cash Conversion Ratio 0.04× 0.32× 1.87× 0.15× 0.45× 0.28×
Accruals Ratio -13.89× -1.06× 0.13× -4.51× -0.84× -1.70×
SBC % of Revenue 33.25% 0.00% 34.62% 10.00%
CapEx Coverage -979.57× -320.98×
Free Cash Flow Per Share $-3.65 $-7.97

Income Statement

Concept FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue from Contract with Customer, Excluding Assessed Tax 135.35K 73.11K 165.80K 310.16K 83.26K
Cost of Revenue 9.99K 14.98K 65.37K 93.39K 12.93K
Gross Profit 125.36K 58.12K 100.43K 216.78K 70.33K
Research and Development Expense 0 3.28K 153.13K 274.26K 115.16K
Operating Expenses 3.39M 2.28M 3.01M 4.03M 4.23M 4.60M
Operating Income (Loss) -3.26M -2.23M -2.91M -3.81M -4.16M -4.60M
Net Income (Loss) Attributable to Parent -18.47M -3.10M -395.58K -17.31M -6.44M -10.81M
Earnings Per Share, Basic $-0.13 $-0.05
Weighted Average Number of Shares Outstanding, Basic 139.21M 59.84M

Balance Sheet

Concept FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash and Cash Equivalents, at Carrying Value 98 85.94K 13.42K 18.89K 379.15K 90.17K
Assets, Current 15.82K 94.86K 46.19K 62.55K 382.50K 111.17K
Assets 1.28M 2.01M 2.61M 3.27M 4.24M 4.61M
Long-term Debt 7.15M 7.26M 6.84M 6.87M 8.16M 7.36M
Liabilities, Current 33.38M 17.70M 16.83M 23.62M 15.48M 13.41M
Liabilities 33.46M 17.78M 16.98M 23.78M 15.63M 14.16M
Stockholders' Equity Attributable to Parent -32.18M -15.77M -14.37M -20.50M -11.39M -9.55M
Common Stock, Shares, Outstanding 213.23M 74.50M 24.54M 1.19M 431,063 316.95M

Cash Flow Statement

Concept FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Cash Provided by (Used in) Operating Activities -678.84K -986.58K -741.59K -2.54M -2.88M -2.99M
Payments to Acquire Property, Plant, and Equipment 2.59K 8.97K
Net Cash Provided by (Used in) Investing Activities -2.59K -8.97K -3.00M
Net Cash Provided by (Used in) Financing Activities 593.00K 1.06M 736.12K 2.18M 3.18M 6.02M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ENDV CIK 0001528172), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SGA

Saga Communications, Inc

BLTE

Belite Bio, Inc

IQST

iQSTEL Inc.